NEBBIOSO, Angela
 Distribuzione geografica
Continente #
EU - Europa 75
AS - Asia 29
NA - Nord America 14
AF - Africa 6
Totale 124
Nazione #
IT - Italia 41
VN - Vietnam 15
US - Stati Uniti d'America 14
IE - Irlanda 12
CN - Cina 9
DE - Germania 9
CZ - Repubblica Ceca 4
NL - Olanda 4
IN - India 3
NG - Nigeria 3
EG - Egitto 2
GB - Regno Unito 2
IR - Iran 2
FR - Francia 1
KE - Kenya 1
RO - Romania 1
UA - Ucraina 1
Totale 124
Città #
Dong Ket 15
Dublin 12
Napoli 10
Caserta 9
Dearborn 4
Naples 4
Bremen 3
Lagos 3
Milan 3
Nola 3
Cairo 2
Dreieich 2
San Giorgio a Cremano 2
Torre Annunziata 2
Wuhan 2
Ann Arbor 1
Aversa 1
Beijing 1
Calvizzano 1
Cambridge 1
Canary Wharf 1
Chengdu 1
Chicago 1
College Station 1
Council Bluffs 1
Eboli 1
Florence 1
Groningen 1
Guangzhou 1
Hefei 1
Horia 1
Muttersholtz 1
Nagpur 1
Nairobi 1
Nuremberg 1
Osnabrück 1
Poli 1
San Jose 1
Shenzhen 1
Tehran 1
Trani 1
Vijāpur 1
Totale 103
Nome #
Cancer epigenetics: Moving forward, file dfd1c04c-1426-0799-e053-6605fe0a8ddb 48
Time-resolved analysis of DNA-protein interactions in living cells by UV laser pulses, file dfd1c04b-bc72-0799-e053-6605fe0a8ddb 18
Forskolin sensitizes human acute myeloid leukemia cells to H3K27me2/3 demethylases GSKJ4 inhibitor via Protein Kinase A, file dfd1c04c-1cb8-0799-e053-6605fe0a8ddb 16
Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes, file dfd1c04a-48bd-0799-e053-6605fe0a8ddb 13
Multi-omics profiling reveals a distinctive epigenome signature for high-risk acute promyelocytic leukemia, file dfd1c04c-1460-0799-e053-6605fe0a8ddb 7
ATTIVATORI DI SIRTUINE E LORO USI, file dfd1c04d-bde0-0799-e053-6605fe0a8ddb 6
Interplay between m6 A epitranscriptome and epigenome in cancer: current knowledge and therapeutic perspectives, file 17bdc4e8-6741-4f4c-94dd-116c50bdc962 5
Preliminary Experience of Liquid Biopsy in Lung Cancer Compared to Conventional Assessment: Light and Shadows, file 72fb2979-9555-4214-9d35-228f3b5bd2cc 4
Identification of a novel quinoline-based DNA demethylating compound highly potent in cancer cells, file dfd1c04c-fec4-0799-e053-6605fe0a8ddb 3
Histone demethylase inhibitors and their potential in cancer treatment, file dfd1c04d-3b6c-0799-e053-6605fe0a8ddb 3
C-Myc modulation and acetylation is a key HDAC inhibitor target in cancer, file dfd1c04b-533d-0799-e053-6605fe0a8ddb 2
Sirtuin Inhibitor Cambinol Induces Cell Differentiation and Differently Interferes with SIRT1 and 2 at the Substrate Binding Site, file 28041731-becf-4124-afad-dc8274c6cd11 1
CBX2 shapes chromatin accessibility promoting AML via p38 MAPK signaling pathway, file 79fc8cbd-dede-4066-a279-b66a69ac6ae5 1
SIRT1 activation promotes energy homeostasis and reprograms liver cancer metabolism, file b3481b7d-4b50-4baf-9954-aea4a6139ea4 1
Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes, file dfd1c04a-8352-0799-e053-6605fe0a8ddb 1
Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect, file dfd1c04c-c5e4-0799-e053-6605fe0a8ddb 1
Structure-activity relationships, biological evaluation and structural studies of novel pyrrolonaphthoxazepines as antitumor agents, file dfd1c04c-d260-0799-e053-6605fe0a8ddb 1
PML-RARalpha/RXR Alters the Epigenetic Landscape in Acute Promyelocytic Leukemia, file dfd1c04c-d2df-0799-e053-6605fe0a8ddb 1
A New Family of Jumonji C Domain-Containing KDM Inhibitors Inspired by Natural Product Purpurogallin, file dfd1c04d-318c-0799-e053-6605fe0a8ddb 1
Marine-Derived Secondary Metabolites as Promising Epigenetic Bio-Compounds for Anticancer Therapy, file dfd1c04d-6393-0799-e053-6605fe0a8ddb 1
Modulatori di Sirtuine, file dfd1c04d-bbce-0799-e053-6605fe0a8ddb 1
Totale 135
Categoria #
all - tutte 512
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 512


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202022 0 0 0 2 5 6 0 3 3 1 1 1
2020/202123 1 1 0 0 2 1 2 0 0 0 0 16
2021/20225 0 0 0 0 0 0 2 0 3 0 0 0
2022/202334 0 2 1 0 4 3 7 2 15 0 0 0
2023/202432 0 1 6 7 8 3 2 5 0 0 0 0
Totale 135